ArticleMicrobiome2023
Dynamics of the gut microbiome, IgA response, and plasma metabolome in the development of pediatric celiac disease.
Article in Microbiome, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Celiac disease and the gut microbiota: bibliometric mapping of research hotspots and immune-mechanistic trends.Frontiers in immunology · 2026Pooled it
- Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease.BMC medicine · 2026Trial
- The plasma metabolome and clinical features of patients with coeliac disease in Northwest China.Annals of medicine · 2026Article
- FMT from Turkish patients with celiac disease is associated with celiac-like enteropathy features in a rat model.BMC gastroenterology · 2026Article
- Epigenetic regulation by gut microbiota-derived metabolites in celiac disease.Biochemistry and biophysics reports · 2026Review
- Comprehensive cross-cohort analysis reveals global gut microbiome signatures of celiac disease.Communications medicine · 2026Article
- Integrated multiomics reveals stable microbe-metabolite relationships in pediatric celiac disease.Frontiers in microbiology · 2026Article
- Gut microbial IgA coating in infants with traditional farming lifestyle and urban infants with allergic outcomes.Frontiers in immunology · 2026Article
- Healthy lifestyle and periodontitis: a multi-omics cross-sectional study in a Chinese cohort.Journal of oral microbiology · 2026Article
- Impact of Parabacteroides distasonis colonization on host microbiome, metabolome, immunity, and diabetes onset.Journal of molecular endocrinology · 2025Article
- Children who develop celiac disease are predicted to exhibit distinct metabolic pathways among their gut microbiota years before diagnosis.Microbiology spectrum · 2025Article
- NIAID workshop on infections and autoimmune diseases.Nature immunology · 2025Article
- Coeliac disease and microbiota: is it time for personalised biotics intervention? A scoping review.BMJ nutrition, prevention & health · 2025Article
- IgG/IgM-coated gut microbiota in schizophrenia: associations with inflammation disease activity.Frontiers in psychiatry · 2025Article
- Integrated analysis of fecal microbiota and metabolomics reveals unique characteristics of asymptomatic and classic celiac disease.Frontiers in microbiology · 2025Article
- Celiac disease and human gut microbiota - how can we study the composition of microorganisms?Przeglad gastroenterologiczny · 2025Review
- Sex-specific cytokine, chemokine, and growth factor signatures in T1D patients and progressors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Protective effect and mechanism of Xiaoyu Xiezhuo decoction on ischemia-reperfusion induced acute kidney injury based on gut-kidney crosstalk.Renal failure · 2024Article
- Review
- Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota-gut-brain axis.Nature reviews. Gastroenterology & hepatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundCeliac disease (CD) is an autoimmune disorder triggered by gluten consumption. Almost all CD patients possess human leukocyte antigen (HLA) DQ2/DQ8 haplotypes; however, only a small subset of individuals carrying these alleles develop CD, indicating the role of environmental factors in CD pathogenesis. The main objective of this study was to determine the contributory role of gut microbiota and microbial metabolites in CD onset. To this end, we obtained fecal samples from a prospective cohort study (ABIS) at ages 2.5 and 5 years. Samples were collected from children who developed CD after the final sample collection (CD progressors) and healthy children matched by age, HLA genotype, breastfeeding duration, and gluten-exposure time (n=15-16). We first used 16S sequencing and immunoglobulin-A sequencing (IgA-seq) using fecal samples obtained from the same children (i) 16 controls and 15 CD progressors at age 2.5 and (ii) 13 controls and 9 CD progressors at age 5. We completed the cytokine profiling, and plasma metabolomics using plasma samples obtained at age 5 (n=7-9). We also determined the effects of one microbiota-derived metabolite, taurodeoxycholic acid (TDCA), on the small intestines and immune cell composition in vivo.
resultsCD progressors have a distinct gut microbiota composition, an increased IgA response, and unique IgA targets compared to healthy subjects. Notably, 26 plasma metabolites, five cytokines, and one chemokine were significantly altered in CD progressors at age 5. Among 26 metabolites, we identified a 2-fold increase in TDCA. TDCA treatment alone caused villous atrophy, increased CD4+ T cells, Natural Killer cells, and two important immunoregulatory proteins, Qa-1 and NKG2D expression on T cells while decreasing T-regulatory cells in intraepithelial lymphocytes (IELs) in C57BL/6J mice.
conclusionsPediatric CD progressors have a distinct gut microbiota composition, plasma metabolome, and cytokine profile before diagnosis. Furthermore, CD progressors have more IgA-coated bacteria and unique targets of IgA in their gut microbiota. TDCA feeding alone stimulates an inflammatory immune response in the small intestines of C57BJ/6 mice and causes villous atrophy, the hallmark of CD. Thus, a microbiota-derived metabolite, TDCA, enriched in CD progressors' plasma, has the potential to drive inflammation in the small intestines and enhance CD pathogenesis. Video Abstract.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.